Core Insights - Beyond Air, Inc. has published a scientific article on the use of intermittent inhaled nitric oxide (iNO) for treating nontuberculous mycobacterial (NTM) lung infections, highlighting its potential as a novel anti-NTM agent [1][2][3] Company Overview - Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on utilizing nitric oxide (NO) to treat respiratory illnesses, neurological disorders, and solid tumors [7][8] - The company has received FDA approval and CE Mark for its LungFit® PH system, aimed at treating hypoxic respiratory failure in neonates [7][11] Clinical Study Details - The LungFit GO NTM Trial was a 12-week, multi-center, open-label clinical trial conducted in Australia, involving 15 adult subjects with chronic refractory NTM lung disease [3][4] - The trial demonstrated high compliance (>90%) with the treatment, and no serious adverse events were reported during the 12-week treatment or follow-up periods [4][5] Efficacy and Safety Findings - Key efficacy endpoints showed meaningful improvements in quality of life, particularly in respiratory symptoms and emotional functioning [5] - Trends in the reduction of microbial load were observed, with one subject achieving culture conversion during the follow-up phase [5] Future Directions - The company plans to further evaluate the efficacy of inhaled NO in larger pivotal studies, as the pilot study results support its potential value [2][3]

"NeuroNOS is a young and radically innovative company, built to think differently and move fast," added Amir Avniel, CEO of NeuroNOS. "In a remarkably short time, we have transitioned from scientific vision to tangible reality—decoding one of the most critical mechanisms in brain diseases and constructing a drug development platform around it. We are already in advanced stages of formulation development and manufacturing, preparing for clinical trials. The brain disease arena is in dire need of breakthrough ...

As the first Beyond Air luminary site, Vanderbilt will help evaluate and showcase the clinical and operational benefits of LungFit® PH, supporting broader awareness and adoption of tankless iNO technology GARDEN CITY, N.Y., March 31, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Vanderbilt Unive ...

VANCOUVER, BC and KIBBUTZ YIFAT, Israel, March 24, 2025 (GLOBE NEWSWIRE) -- Beyond Oil Ltd. (CSE: BOIL) (OTCQB: BEOLF) (Frankfurt: UH9) (“Beyond Oil” or the “Company”), a food-tech innovation company dedicated to reducing health risks associated with fried food while lowering operational costs, minimizing waste, and enhancing sustainability, is pleased to announce that further to its news release on February 28, 2025, it has received full payment for its upcoming initial 6-tonne (T) shipment to Deep Frying ...

First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of quality Currently in the advanced stages of formulation development for subcutaneous injection, with plans for an oral formulation BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and other complex neurological conditions, including Alzheimer’s di ...

VANCOUVER, BC and KIBBUTZ YIFAT, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- Beyond Oil Ltd. (CSE: BOIL) (OTCQB: BEOLF) (Frankfurt: UH9) (“Beyond Oil” or the “Company”), a food-tech innovation company dedicated to reducing health risks associated with fried food while lowering operational costs, minimizing waste, and enhancing sustainability, is pleased to announce that it has signed its first distribution agreement (the “Agreement”) in Portugal with Serious Formula Ltd (“Serious Formula” or the “Distributor ...

Core Insights - Beyond Air, Inc. has expanded its international distribution network for the LungFit PH system, now covering 18 countries following new agreements in France, Turkey, Romania, and Morocco [1][2] - The company anticipates a rapid commercial ramp-up in international markets, leveraging established distribution partners with medical device infrastructure [2] Distribution Agreements - Recent agreements include partnerships with EUROCARE for France, Medelart Healthcare for Turkey, Abb Neopuls for Romania, and OXYPLUS for Morocco [1][2] - The current distribution partners also include Getz Healthcare across multiple Asian countries, Saudi Health Services CO in Saudi Arabia, and MDC Care Medical Trading in the UAE and surrounding regions [2] Product Overview - LungFit PH is a tankless system that generates nitric oxide (NO) from room air, enhancing operational efficiency and supporting sustainability in hospital settings [3][4] - The device can deliver NO at concentrations ranging from 1 ppm to 80 ppm, with potential applications in treating severe acute lung infections and chronic lung infections [4][5] Regulatory Status - LungFit PH is approved for commercial use in the United States, European Union, Australia, Thailand, and New Zealand [6] - The system is designated as a medical device by the U.S. FDA and is intended for use in treating hypoxic respiratory failure in neonates [9] Therapeutic Applications - Nitric oxide plays a critical role in various biological functions and is used in treating conditions such as adult respiratory distress syndrome and persistent pulmonary hypertension [7] - Exogenous inhaled NO is believed to have antimicrobial properties, potentially effective against a range of pathogens, including multi-drug-resistant strains [8]

GARDEN CITY, N.Y., March 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in the Roth 37th Annual Growth Stock Conference being held March 16-18, 2025 in Laguna, CA and the Jones Healthcare and Technology Innovatio ...

VANCOUVER, BC and KIBBUTZ YIFAT, Israel, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Beyond Oil Ltd. (CSE: BOIL) (OTCQB: BEOLF) (Frankfurt: UH9) (“Beyond Oil” or the “Company”), a food-tech innovation company dedicated to reducing health risks associated with fried food while lowering operational costs, minimizing waste, and enhancing sustainability, is pleased to announce that it has signed a distribution agreement (the “Agreement”) with Deep Frying Solutions Pvt Ltd, a newly formed company based in Gujarat, India ( ...

VANCOUVER, B.C. and KIBBUTZ YIFAT, ISRAEL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Beyond Oil Ltd. (CSE: BOIL) (OTCQB: BEOLF) (Frankfurt: UH9) (“Beyond Oil” or the “Company”), a food-tech innovation company dedicated to reducing health risks associated with fried food while lowering operational costs, minimizing waste, and enhancing sustainability, is pleased to announce its entry into the African market through a new distribution agreement with Minrosolve Proprietary in South Africa. This agreement marks Beyond ...